<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731636</url>
  </required_header>
  <id_info>
    <org_study_id>TAAA-FIM-001</org_study_id>
    <nct_id>NCT04731636</nct_id>
  </id_info>
  <brief_title>Guo's Visceral Arteries Reconstruction: First in Man Study</brief_title>
  <official_title>Guo's Visceral Arteries Reconstruction :The First in Man Study of G-Branch Multiple Branch Stent Graft System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A First in man study to evaluate the safety and efficacy of thoracoabdominal aortic stent&#xD;
      system for endovascular treatment of thoracoabdominal aortic aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is mainly for patients with Crawford type I-V thoracoabdominal aortic aneurysms,&#xD;
      and all subjects who passed the screening and signed the informed consent will be enrolled.&#xD;
      Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be&#xD;
      implanted with thoracoabdominal aortic stent system.&#xD;
&#xD;
      Patients will be followed up at discharge, 1 month, 6 months, 12 months after the&#xD;
      implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Major Adverse events (MAE) within 30 days postoperative</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Major Adverse events (MAE) are defined as all-cause death, liver failure, intestinal necrosis, splenic infarction, renal infarction, renal failure, cerebral infarction, paraplegia, myocardial infarction, and respiratory failure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Thoracoabdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Crawford type I-V thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G-Branch thoracoabdominal aortic stent system</intervention_name>
    <description>Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged greater than 18 years old and less than 85 years old;&#xD;
&#xD;
          2. Patients diagnosed with Crawford type I-V Thoracoabdominal Aortic Aneurysms and should&#xD;
             meet at least one of the following conditions:&#xD;
&#xD;
               1. The maximum diameter of Thoracoabdominal Aortic Aneurysms &gt;50mm;&#xD;
&#xD;
               2. The diameter increased by more than 5mm in the last 6 months;&#xD;
&#xD;
               3. The maximum diameter of Thoracoabdominal Aortic Aneurysms &gt;45mm, with clear&#xD;
                  abdominal pain, low back pain and other symptoms;&#xD;
&#xD;
          3. Patients with thoracoabdominal aortic aneurysms who need to reconstruct the important&#xD;
             branches of abdominal viscera; The important branches of abdominal viscera include&#xD;
             superior mesenteric artery, celiac trunk and left and right renal artery;&#xD;
&#xD;
          4. The range of the proximal aneurysm neck diameter of the thoracoabdominal aortic&#xD;
             aneurysm is between 17mm to 42mm;&#xD;
&#xD;
          5. The length of the proximal aneurysm neck of the thoracoabdominal aortic aneurysm≥25mm;&#xD;
&#xD;
          6. The range of the distal anchoring area diameter of the thoracoabdominal aortic&#xD;
             aneurysm is between 12mm to 25mm;&#xD;
&#xD;
          7. The length of the distal anchoring area of the thoracoabdominal aortic aneurysm ≥15mm;&#xD;
&#xD;
          8. The range of the anchoring area diameter of the important branches of abdominal&#xD;
             viscera is between 4mm to 13mm;&#xD;
&#xD;
          9. The length of the anchoring area of the important branches of abdominal viscera≥15mm;&#xD;
&#xD;
         10. Patients who need to use a abdominal aortic bifurcation stent system should also meet&#xD;
             the following conditions:&#xD;
&#xD;
               1. The range of the diameter of the iliac artery anchoring area is between 8mm to&#xD;
                  26mm;&#xD;
&#xD;
               2. The length of the iliac artery anchoring area≥15mm;&#xD;
&#xD;
         11. The patients had suitable iliac, femoral, brachial and axillary artery approaches;&#xD;
&#xD;
         12. Patients who can understand the purpose of the trial, voluntarily participate in and&#xD;
             sign the informed consent, and are willing to complete the follow-up according to the&#xD;
             requirements of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with rupture of the thoracoabdominal aortic aneurysm;&#xD;
&#xD;
          2. Patients with thoracoabdominal aortic dissection;&#xD;
&#xD;
          3. Patients with mycotic or infectious thoracoabdominal aortic aneurysms;&#xD;
&#xD;
          4. Patients who need to reconstruct bilateral internal iliac arteries;&#xD;
&#xD;
          5. Patients with severe stenosis, calcification, or mural thrombus in the anchoring area&#xD;
             of the stent and easily lead to incomplete stent apposition;&#xD;
&#xD;
          6. Patients with a history of myocardial infarction or unstable angina pectoris for 6&#xD;
             months. Characteristics of unstable angina pectoris: angina symptoms gradually&#xD;
             increased, new onset of rest or night angina pectoris or occurrence of angina&#xD;
             prolonged;&#xD;
&#xD;
          7. Patients with any transient ischemic attack (TIA) or ischemic stroke within 3 months;&#xD;
&#xD;
          8. Patients with a history of allergy to contrast media, stents and conveyor materials&#xD;
             (including nickel and titanium, polyester, PTFE, and nylon polymer materials);&#xD;
&#xD;
          9. A patient with connective tissue diseases such as Marfan syndrome, Eaton syndrome, or&#xD;
             Bessel's disease;&#xD;
&#xD;
         10. Patients with arteritis;&#xD;
&#xD;
         11. Patients with major organ failure or other serious diseases;&#xD;
&#xD;
         12. Patients who were not suitable for endovascular treatment, judged by the investigator;&#xD;
&#xD;
         13. Pregnant or lactating women or women who plan to get pregnant.&#xD;
&#xD;
         14. The patients participated in other clinical trials and did not come out of the group&#xD;
             or withdraw within the first 3 months of the screening period of this trial;&#xD;
&#xD;
         15. Life expectancy is less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Xu</last_name>
    <phone>15695219339</phone>
    <phone_ext>86</phone_ext>
    <email>xuwei@lifetechmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Guo</last_name>
    </contact>
    <investigator>
      <last_name>Wei Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lifetech Scientific (Shenzhen) Co., Ltd.</investigator_affiliation>
    <investigator_full_name>XuWei</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <keyword>Guo's Visceral Arteries Reconstruction</keyword>
  <keyword>Thoracoabdominal aortic stent system</keyword>
  <keyword>Thoracoabdominal Aortic Aneurysms</keyword>
  <keyword>G-Branch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

